The end of systemic anticoagulation therapy for restenosis prevention.
Dangas
G
G
Cardiovascular Research Foundation, Lenox Hill Heart and Vascular Institute, 55 East 59th Street, 6th Floor, New York, NY 10022, USA. gdangas@crf.org
Iakovou
I
I
D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000150:complications / Q000628:therapy; D023903:Coronary Restenosis / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control*; D016503:Drug Delivery Systems; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; C403769:certoparin